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Abstract
Background—Full-field digital mammography (FFDM) has largely replaced screen-film
mammography (SFM) for breast cancer screening, but how this affects downstream breast-related
use and costs is unknown.
Objectives—To compare breast-related healthcare use and costs among Medicare beneficiaries
undergoing SFM versus FFDM from 1999 to 2005.
Design—Retrospective cohort study.
Subjects—Medicare-enrolled women ages 66 and older with mammograms in Breast Cancer
Surveillance Consortium registries.
Measures—Subsequent follow-up with additional imaging or breast biopsy within 12 months
was ascertained through Medicare claims. Associated mean costs were estimated by screening
modality and year, adjusting for confounding factors and clustering within mammography
facilities using Generalized Estimating Equations.
Results—Among 138,199 women, 332,324 SFM and 22,407 FFDM mammograms were
analyzed. Approximately 6.5% of SFM and 9.0% of FFDM had positive findings. In 2001
subsequent imaging was higher among FFDM versus SFM (127.5 vs. 97.4 follow-up
mammography claims per 1000 index mammograms) whereas subsequent biopsy was lower
among FFDM versus SFM (19.2 vs. 24.9 per 1000 index mammograms) with differences
decreasing over time. From 2001 to 2004, mammography subsequent to FFDM had higher mean
costs than SFM ($82.60 vs. $64.31 in 2001). The only cost differences between SFM and FFDM
for ultrasound or biopsy were in 2001.
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Conclusions—Subsequent breast-related healthcare use differed early in FFDM introduction,
but diminished over time with differences attributable to higher recall rates for additional imaging
and lower rates of biopsy in those undergoing FFDM vs. SFM. Remaining cost differences are due
to higher reimbursement rates for FFDM vs. SFM.
Keywords
Mammography screening; Full Field Digital; Cost; Medicare; work-up; false positive; health
services
Introduction
There is little controversy that the best approach for decreasing breast cancer morbidity and
mortality among most women includes mammography screening for early detection.1,2
Mammography screening reduces breast cancer mortality by 15%-32% for women aged
40-69.2,3 Comparative effectiveness research (CER) has shown that full field digital
mammography (FFDM) is superior to screen film mammography (SFM) in terms of cancer
detection in pre- and peri- menopausal women, women less than 50 years and women with
dense breasts, but found no overall difference between the modalities.4-6 Among women
ages 65 years and older with non-dense breasts the Digital Mammography Imaging
Screening Trial (DMIST) reported greater sensitivity of SFM compared to FFDM, though
this difference was not statistically significant.7
Despite limited evidence of superior performance, FFDM use has diffused rapidly in the US;
it is currently estimated to comprise 79% of all mammography machines8 and FFDM is
anticipated to fully replace SFM over time. Currently Medicare reimburses screening SFM
and FFDM at average rates of $78 and $129 respectively. The higher cost of FFDM is linked
to the cost of purchasing and maintaining the digital machines as well as the increased time
it takes to interpret FFDM9 due to computer manipulation time.10
While DMIST reported that FFDM is not cost-effective relative to SFM for women aged 50
years or older,11 the trial was not able to evaluate follow-up care costs between modalities
because all women were screened with both modalities. The SFM and FFDM mammograms
were interpreted independently by different radiologists and follow-up care was undertaken
to pursue screening abnormalities detected with either modality. It is unknown whether
downstream breast-related healthcare use and costs vary by initial screening modality (SFM
vs. FFDM) once an abnormal finding is reported.
Understanding the downstream health service use following the introduction of digital
mammography is an important part of documenting the health and economic impact of the
transition to this new technology. Using data from the Breast Cancer Surveillance
Consortium (BCSC) and linked Medicare claims data, we examined breast-related
healthcare use and costs in the year following screening mammography among women ages
66 years and older over the period 1999 to 2005. We assessed differences in these outcomes




The BCSC is a national network of mammography registries organized to assess breast
cancer screening practices and outcomes in the U.S.12,13 Data were obtained from four
BCSC registries participating in a linkage of BCSC records and Medicare claims data:
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Carolina Mammography Registry; New Hampshire Mammography Network; San Francisco
Mammography Registry; and Vermont Breast Cancer Surveillance System. Registries
collected data from community radiology facilities including patient characteristics and
clinical information at each mammogram. Radiologists’ assessments and recommendations
were based on the American College of Radiology's Breast Imaging Reporting and Data
System (BI-RADS®).14 Breast cancer diagnoses and tumor characteristics were obtained by
linking BCSC data to hospital-based pathology services, regional Surveillance,
Epidemiology, and End Results (SEER) programs, and state tumor registries. Data were
pooled at the central Statistical Coordinating Center (SCC). Registries and the SCC received
Institutional Review Board approval for active or passive consenting processes or a waiver
of consent to enroll participants, link data, and perform analyses. All procedures were
Health Insurance Portability and Accountability Act compliant, and registries and the SCC
received a Federal Certificate of Confidentiality and other protections for the identities of
women, physicians, and facilities.
Women receiving mammograms at one of the four registries participating in the Medicare
linkage who were ages 65 and older and enrolled in Medicare between 1998 and 2006 were
matched to the Center for Medicare and Medicaid Services’ (CMS) Medicare Program
Master Enrollment file by unique identifiers (86.8% match rate). Medicare enrollment
information for this period and Medicare claims data from MedPAR, Outpatient, and Carrier
files were included in the database.
Participants
Women receiving a screening mammogram (determined by radiologist's indication)13 within
the participating registries were included if they were at least age 66 years or older at the
time of the screening mammogram, continuously enrolled in fee-for-service Medicare Parts
A and B and not enrolled in a Medicare HMO for one year before or after the mammogram,
and had no prior history of breast cancer. We limited the study to women at least 66 years of
age at the time of screening mammogram and those with two years of continuous Medicare
enrollment (one year before and one year after the screening mammogram) in order to
ensure complete capture of claims data. We included the 96.5% of BCSC database
mammograms with a corresponding Medicare claim within 7 days before or after the exam
date recorded in the BCSC database.
Measures and definitions
We used standard BCSC definitions to assign mammogram outcome.13 A mammogram was
considered positive if the BI-RADS® assessment following the initial screening
mammogram (initial assessment) was: 0 (needs additional imaging evaluation); 4
(suspicious abnormality); 5 (highly suggestive of malignancy); or 3 (probably benign
finding) with a recommendation for immediate follow-up. Mammograms were defined as
true-positive (TP) or false-negative (FN) if a diagnosis of invasive carcinoma or ductal
carcinoma in situ occurred within 1 year after the screening examination or before the next
screening mammogram, whichever occurred first.13 Mammograms with no diagnosis of
invasive carcinoma or ductal carcinoma in situ within 1 year of the screening mammogram
or prior to the next mammogram were classified as false-positive (FP) or true-negative (TN).
Self-reported data on age, race, Hispanic ethnicity, personal history of breast cancer, family
history of breast cancer in a first-degree relative, and previous mammography were collected
at each mammogram. BI-RADS14 breast density was assigned by the interpreting
radiologist.
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We examined follow-up services related to the diagnostic work-up of mammograms as:
mammography, ultrasound, or breast biopsy/other invasive breast procedure using claims
identified on the basis of International Classification of Disease, Ninth Revision (ICD-9)
procedure and diagnosis codes, Healthcare Common Procedure Coding System (HCPCS)
codes, and diagnosis-related groups (see Table, Supplemental Digital Content 1). We also
created a category of any follow-up which included any of the above services. For each
follow-up type, we identified the total number of days on which a claim occurred in the
Medicare files in the year subsequent to the index screening mammogram. Procedures of
multiple types (e.g. mammography and ultrasound) occurring on the same day were counted
separately whereas multiple claims for procedures of a single type (e.g. multiple
mammography claims) were counted as a single visit. We also identified the number of
unique days in which mammography, ultrasound or breast biopsy/other invasive breast
procedure appeared in the Medicare files in the year preceding the index screening exam for
adjustment purposes.
We calculated Medicare reimbursed amounts for each type of follow-up for the year before
(for adjustment purposes) and after the index mammogram. Medicare reimbursement for
professional and facility charges were based on the Resource Based Relative Value Scale
methodology, which assigns costs on the basis of HCPCS, with regional modifiers to allow
for differences in cost of medical care throughout the U.S.15 Inpatient service costs were
based on the Diagnosis Related Groups (DRG). Because our goal was to examine the costs
to Medicare for breast-related health care use, the analytic perspective taken was that of the
Center for Medicare and Medicaid Services (CMS). Medicare pricing was relatively
constant over the study time period; hence, due to the similarity between real and nominal
dollars to CMS over this period, we report observed payments instead of indexing costs to a
single year.
Statistical Analysis
We estimated the distribution of patient- and mammogram-level characteristics by index
screening mammogram modality. We computed the count and proportion of screening
mammograms with subsequent utilization for each follow-up type, overall and separately by
year and modality of the index examination. Among screening mammograms with at least
one claim for follow-up breast-related care, we estimated the mean and standard deviation of
costs, overall and separately by year and modality of the index examination. These statistics
were also computed stratified by TN and FP mammography outcomes. We limited the
stratified results to those without a cancer endpoint because of the relatively small number
of cancer cases and the difficulty in using claims to determine when diagnostic workup ends
and cancer treatment begins. We estimated means rather than medians to allow for
extrapolation of our findings to the population level (mean cost x number of women in
population = total cost for population). In addition, we calculated and compared the
sensitivity and specificity with 95% confidence intervals (95%CI) of SFM and FFDM over
time.
We modeled the probability of subsequent breast-related follow-up and the total cost of
follow-up by service type (mammography, ultrasound, breast biopsy/other invasive breast
procedure, and any follow-up) as a function of modality and year of the index screening
exam while adjusting for possible confounding factors and clustering within mammography
facilities using Generalized Estimating Equations. Multivariable models were adjusted for
age, race/ethnicity, breast density, first degree family history of breast cancer, breast-related
use or cost in the prior year, screening interval, and BCSC registry. Cost models were
estimated only among women who had any additional costs in the subsequent year and
therefore estimate mean cost among women who received subsequent breast-related health
care. Models were used to generate standardized estimates of the probability of use and the
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cost of follow-up in each year subsequent to FFDM and SFM via indirect standardization.
Estimates were standardized to the distribution of patient characteristics represented by the
total population of index mammograms. We report point estimates and 95% confidence
intervals generated by these models.
Analyses were performed using R 2.10.1 (R Foundation for Statistical Computing, Vienna,
Austria).
Results
A total of 332,324 SFM and 22,407 FFDM from 138,199 women from 139 mammography
facilities (72 in North Carolina, 33 in New Hampshire, 18 in San Francisco and 16 in
Vermont) were performed between 1999 and 2005 (Table 1). BCSC facilities first began
performing FFDM in 2001 with 802 (1.6%) screens. By 2005 the number of FFDM screens
increased to 8,640 (17.5%). The majority of SFM and FFDM were among white non-
Hispanic women and among women ages 66-74 years. The majority of women had no first
degree family history of breast cancer and were not using hormone therapy. Most women
had scattered fibroglandular breast density. Positive findings were reported for 6.5% of SFM
and 9.0% of FFDM. The cancer rate within one year of screening mammogram and prior to
the next screening mammogram was 0.7% among SFM and 0.6% among FFDM screens.
Due to few cancer events in the FFDM group, comparison of sensitivity between SFM and
FFDM is inappropriate. The specificity of SFM and FFDM remained relatively constant
during the study period, yet the specificity of FFDM is consistently lower than the
specificity of SFM (in 2005 specificity was 91.6% (95%CI: 91.0, 92.2) versus 94.4%
(95%CI: 94.1, 94.6) respectively).
Of the 49,941 screening mammograms performed in 2001, 9.5% of SFM and 13.7% of
FFDM had a subsequent mammogram in the following year, 3.4% of SFM and 7.7% of
FFDM had an ultrasound visit, and 2.2% of SFM and 2.2% of FFDM had a breast biopsy/
invasive breast procedure (Table 2). Among index screening mammograms with a follow-up
mammogram, approximately 97% of initial SFM were followed by SFM and 92% of initial
FFDM were followed by FFDM. A higher proportion of FFDM had a subsequent
mammogram or ultrasound compared with SFM in all years from 2001 to 2005. There was
no difference in the proportion of SFM vs. FFDM with a breast biopsy/invasive procedure in
the year after the screening mammogram.
The unadjusted number of subsequent claims (separately for mammography, ultrasound, and
breast biopsy) per 1,000 index screening mammograms and the unadjusted mean costs in the
following year by calendar year and screening modality are shown in Table 3. In 1999 for
every 1,000 screening mammograms performed, Medicare received 107.5 claims for
additional mammograms in the subsequent year. The number of claims for subsequent
mammography was higher for FFDM compared to SFM from 2001 to 2005 but the gap
narrowed over time. Similar patterns were seen for ultrasound claims in the year after initial
screening mammography, but not for breast biopsies/other invasive procedures. For women
with at least one subsequent mammography claim, the mean number of mammograms in the
year following initial SFM and FFDM were similar (1.25 versus 1.27, respectively). In 1999
the mean cost to Medicare of subsequent mammography for SFM was $49.10. The mean
cost of subsequent mammography claims increased over time for both SFM and FFDM. In
2001, the mean cost of subsequent mammography in the year following a SFM was $54.00
compared to $65.40 for FFDM. By 2005 the cost of subsequent mammography had
increased to $111.60 for SFM and $131.70 for FFDM.
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The adjusted number of screening mammograms with subsequent mammography was
significantly higher for FFDM compared to SFM in 2001-2003 (p = 0.009, 0.03, and 0.03,
respectively) (Figure 1A). No difference was observed in rates of subsequent mammography
use between SFM and FFDM among women with TN index mammograms. However,
among women with FP index mammograms, significant differences were observed across
most years (p <0.05 for all years except 2004). Significantly more FFDM index
mammograms received subsequent ultrasound compared to SFM in 2001-2003 (Figure 1B).
The adjusted number of subsequent ultrasound claims decreased in 2002 for FFDM and by
2005 there was no difference between FFDM and SFM. For breast biopsies/other invasive
procedures, the adjusted number of claims were significantly lower both overall and among
TN and FP index mammograms for FFDM compared to SFM in 2001 (p < 0.05). No
significant differences were observed in other years (Figure 1C). Patterns of adjusted
subsequent use for any follow-up are similar to those observed for subsequent
mammography because the majority of follow-up involved use of subsequent
mammography (Figure 1D).
In adjusted analyses, the costs of subsequent mammography were higher among FFDM
compared to SFM in 2001-2004. of modality, the costs increased over time (Figure 2A).
Among women with subsequent ultrasound, costs differed significantly by screening
modality only in 2001 ($66.65 for SFM vs. $55.81 for FFDM, p <0.0001) (Figure 2B). For
women receiving follow-up biopsies/invasive breast procedures, differences in cost by
screening modality were evident in 2001 ($566.47 for SFM vs. $292.64 for FFDM,
p=0.002), and among women with TN results in 2001 and 2002 (Figure 2C). The costs of
any follow-up were higher for FFDM versus SFM among women with a TN result in 2001
and 2002 but were lower for FFDM versus SFM among women with a FP result in 2001
(Figure 2D).
Discussion
Downstream mammography and ultrasound use in the year after a screening mammogram
was more common among FFDM versus SFM in the year when FFDM first became
available (2001), with differences decreasing over time after the initial introduction of
FFDM. Increases in subsequent mammography and ultrasound following FFDM versus
SFM were observed among women with FP mammograms, suggesting that differences in
utilization were not only attributable to higher recall rates in the early years of FFDM but
represent increased use of imaging among recalled women whose index modality was
FFDM. These differences in the early years of FFDM decrease over time, which may
indicate a learning curve associated with diffusion of new technology.16 Our analysis did not
address the timing of transition to FFDM within each facility, but focused instead on overall
trends in use of breast-related services and costs following mammography screening over
years when FFDM became increasingly available.
Two previous studies from Norway suggest there is an important learning curve for FFDM.
The Oslo I trial17 found higher recall rates with FFDM versus SFM (12% vs. 7%) and the
Oslo II trial18 found higher cancer detection rates with FFDM compared to SFM. In these
prior studies, the authors speculated that the higher recall rates seen with FFDM could be
explained by a learning curve effect. In another BCSC study using data from 1996 to 2005,
we examined the performance of 231 radiologists on SFM. Radiologists’ interpretations of
screening mammograms improved over time with additional residency training and targeted
continuing medical education proved beneficial in reducing the number of work-ups for
benign lesions.19 We would expect to see a similar learning curve with regard to FFDM as
radiologists read more FFDM screens and in fact, this pattern was observed.
Henderson et al. Page 6













Not surprisingly, we report higher follow-up mammography costs over time from 1999 to
2005. We found that higher costs of subsequent mammography for FFDM were partly
attributable to a higher proportion of FFDM being followed up with additional FFDM while
SFM tended to be followed by SFM. Since FFDM has a higher reimbursement rate than
SFM, the conversion to FFDM is increasing not just the initial screening mammogram cost,
but also the overall costs associated with screening. Higher healthcare costs were associated
with downstream mammography for FFDM compared to SFM from 2001 to 2005, but not
higher costs for ultrasound and breast biopsies or other invasive procedures. Higher
downstream costs associated with FFDM could not be attributed to receipt of more
mammography among those with FFDM since the mean number of mammograms in the
year following initial SFM and FFDM were similar.
Increases in downstream healthcare use and cost among FP mammograms relative to TN
mammograms were expected since abnormal mammogram screening results are followed
with additional imaging (diagnostic mammogram, targeted breast ultrasound, or breast
MRI)20,21 or breast biopsy/procedure. A 2010 study examining breast-related care costs in
the year after a FP screening mammogram among women ages 40-80 years enrolled in an
HMO in Washington state found breast-related healthcare costs following a FP mammogram
were approximately $500 more than for TN mammograms.22 The DMIST also reported
increased costs of subsequent breast-related care among FP and TP mammograms but
DMIST was unable to examine differences by modality since all women had both SFM and
FFDM.11 Our finding that diagnostic mammograms are done using the same modality as the
screening mammogram in the vast majority of cases, supports this assumption made in the
DMIST cost-effectiveness analysis.
Our study used Medicare administrative data that rely on billing codes to identify
subsequent breast-related healthcare use; thus, it is possible that we might not capture all
follow-up visits. There is no reason to believe that there was differential ascertainment of
healthcare use for women receiving SFM versus FFDM, so our results are not biased with
respect to differences in relative health care use related to screening modality. Trends and
patterns in subsequent breast-related healthcare use and cost might be different among
women younger than 66 years or among women with private health insurance. There were a
small number of FFDM exams in 2001 but this number increased substantially during the
five year study period.
The use and costs of downstream breast imaging increased substantially over time, with
some of the observed increases in cost attributable to greater use of FFDM which is
reimbursed at a higher rate than SFM. The ability to measure the downstream burden on the
healthcare system following the diffusion of new technology is an important element in its
evaluation over and above performance characteristics. These long-term effects (subsequent
use and cost of health services) need to be quantified if they are going to be considered in
CER aimed at understanding the implications of implementing new technology. In the case
of FFDM, adoption is inevitable given the persistent increase in facilities with certified
FFDM units, currently representing 80% of mammography facilities and 82% of all
mammography units.23 Our study documents that early in the transition period, FFDM had
higher downstream costs than SFM and that these were largely due to the higher
reimbursement rate for FFDM compared with SFM.
Using digital mammography as a case study, we have shown how registry and
administrative claims data may be used to examine the resource use and cost consequences
of adopting a new screening modality. Our approach of combining registry and claims data
may serve as a paradigm for assessing the real-life consequences of new screening
technology adoption and diffusion. With the advent of new effective advanced imaging
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technologies for screening (e.g. spiral CT and lung cancer) it is important to consider
claims-based analyses to uncover downstream cost consequences of technology adopotion.
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Trends in the adjusted number of women with subsequent claims (separately for
mammography (1A), ultrasound (1B), and breast biopsy (1C) and a combined total for any
breast-related follow-up (1D)) per 1000 index mammograms, by mammogram result (true
positive + false positive (TN+FP), TN, and FP) and screening modality. Full field digital
mammography is indicated with white circles and screen film mammography is indicated
with black circles.
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Trends in the adjusted subsequent costs (separately for mammography (2A), ultrasound
(2B), and breast biopsy (2C), and a combined total for any breast-related follow-up (2D))
per index mammogram with non-zero subsequent costs, by mammogram result (true
positive + false positive (TN+FP), TN, and FP) and screening modality. Full field digital
mammography is indicated with white circles and screen film mammography is indicated
with black circles.
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Table 1
Characteristics of the Index Screening Mammograms
Characteristic Screen-Film N=332,324 Digital N=22,407
N % N %
Age group, years
66-74 193,029 58.1 13,059 58.3
75-84 122,220 36.8 8,040 35.9
85+ 17,075 5.1 1,308 5.8
Race/ethnicity
White, non-hispanic 262,332 85.8 19,151 90.4
Black, non-hispanic 25,900 8.5 474 2.2
Asian 10,527 3.4 1,152 5.4
Am Indian/Alaska native 1,490 0.5 23 0.1
Hispanic 5,481 1.8 393 1.9
Missing 26,594 -- 1,214 --
Family history of breast cancer
Yes 45,668 17.0 3,903 19.4
No 222,455 83.0 16,252 80.6
Missing 64,201 -- 2,252 --
Hormone therapy use
Yes 56,246 18.7 2,160 10.9
No 243,863 81.3 17,663 89.1
Missing 32,215 -- 2,584 --
BIRADS breast density
1 – Almost entirely fat 30,050 10.4 2,134 10.2
2 – Scattered fibroangular tissue 163,747 56.7 10,642 51.0
3 – Heterogenously dense 86,741 30.0 7,716 37.0
4 – Extremely dense 8,497 2.9 388 1.9
Missing 43,289 -- 1,527 --
Mammogram finding
Negative 310,853 93.5 20,394 91.0
Positive 21,471 6.5 2,013 9.0
Months since previous mammogram
9-18 242,167 75.9 18,503 83.4
18-30 48,223 15.1 2,276 10.3
31-42 14,533 4.6 685 3.1
>42 14,034 4.4 724 3.3
Missing 13,367 -- 219 --
Cancer within 1 year
Yes 2,315 0.7 139 0.6
No 330,009 99.3 22,268 99.4
Year of mammogram
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Characteristic Screen-Film N=332,324 Digital N=22,407
N % N %
1999 44,055 13.3 -- --
2000 45,641 13.7 -- --
2001 49,139 14.8 802 3.6
2002 55,425 16.7 2,300 10.3
2003 51,843 15.6 4,513 20.1
2004 45,378 13.7 6,152 27.5
2005 40,843 12.3 8,640 38.6
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